Pulse Biosciences (PLSE) On Thyroid Data And Losses Has An Undervalued Narrative
Pulse Biosciences (PLSE) has drawn attention after reporting third quarter 2026 results, showing a net loss alongside fresh six month clinical data from its PRECISE-BTN thyroid nodule study.
Pulse Biosciences’ share price has surged over 330% year to date and climbed 31% over the past 90 days. The recent 9% one day move to $58.17 suggests momentum has strengthened as traders weigh the PRECISE-BTN data against ongoing losses and past multi year total shareholder returns in the hundreds of percent.
Scan how Pulse Biosciences fits alongside other fast moving healthcare names by reviewing the hand picked 36 healthcare AI stocks now shaping this corner of the market.
Pulse Biosciences now sits at the junction of a fast rising share price, promising thyroid data and a widening loss line. The key question is whether the recent move is pricing in too much hope or too little, once you run the valuation numbers next.
Most Popular Narrative: 13% Undervalued
The analyst consensus Narrative on Simply Wall St pegs Pulse Biosciences at a fair value of $66.67, compared with the latest close at $58.17. This frames the current move as still short of that central estimate while keeping the focus tightly on clinical and commercial execution.
Growing clinical evidence through PRECISE BTN, NANOCLAMP AF, and European feasibility studies is expected to strengthen reimbursement, support guideline inclusion, and drive higher procedure adoption, improving revenue visibility and operating leverage as fixed R&D and commercial infrastructure is spread over a larger sales base.
See why 3 investors see Pulse Biosciences as 13% undervalued.
Result: Fair Value of $66.67 (UNDERVALUED)
Still, the narrative can crack if reimbursement support lags or if high operating costs against US$1.5 million of revenue keep Pulse Biosciences’ losses deep for longer.
Find out about the key risks to this Pulse Biosciences narrative.
Another View On Pulse Biosciences’ Valuation
Analyst targets frame Pulse Biosciences as undervalued, yet our DCF model tells a very different story. On those future cash flow assumptions, fair value lands at about $16.19 per share, far below the current $58.17 price. That gap points to optimism already embedded, so which lens do you trust more?
Look into how the SWS DCF model arrives at its fair value.
Next Steps
Mixed messages on Pulse Biosciences so far. If you want to move quickly and base your stance on more than headlines, consider reviewing the 1 key reward and 2 important warning signs.
Looking For More Investment Ideas Beyond Pulse Biosciences?
If Pulse Biosciences has sharpened your focus on opportunity and risk, do not stop here. Broaden your watchlist with other clearly defined ideas using the Simply Wall St screener.
- Target higher potential upside by scanning selectively through the 19 high quality undiscovered gems that combine strong fundamentals with less crowded ownership.
- Strengthen your defensive side by reviewing a 30 resilient stocks with low risk scores that prioritises resilient balance sheets and lower historical volatility.
- Anchor your portfolio with stability by assessing a list of solid balance sheet and fundamentals (25 results) that filters for companies with stronger finances and healthier cash positions.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com